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Introduction

54
More than 100 neuropeptides are expressed in different neuronal subpopulations.
55
Whereas neurotransmitters are packaged in abundant small vesicles targeted to nerve endings, 56 peptides are packaged in large vesicles that are relatively sparse, and which can be released 57 from all compartments of a neuron. These vesicles carry a large cargo (~85,000 molecules of 58 oxytocin) and peptides act at receptors with nanomolar affinity (1) concentration of 1pg/ml for 30 days, and a concentration of 10pg/ml, as seen during water 82 deprivation, for three days (1) .
83
Between the blood and interstitial fluid of the body there is no barrier to the passage 84 of peptides, so the distribution volume for oxytocin is much larger than the plasma volume 85 (7). Oxytocin is stable in plasma (except in pregnancy, when oxytocinase is abundant), and is 86 cleared from the blood via the kidneys and liver. In the rat, at i.v. doses of up to 500ng/kg, 87 oxytocin disappears from the blood with a half-life of 3-8min (8). The half-life in CSF is 88 longer: 28min in guinea pig (9), and 19min in rat (10). Oxytocin is thought to be cleared from
89
CSF by a combination of flow into the subarachnoid space (11), and active transport into 90 blood (12).
91
In man, the pituitary oxytocin content (estimated by bioassay) is ~14IU (28µg) (13).
92
Circulating concentrations are (as in the rat) ~1-10pg/ml, and the pharmacokinetics after i.v.
93
injection fit a two-compartment model, with a distribution volume of ~33L, a distribution 94 half-life of ~3min and an elimination half-life of ~20min (14). As in the rat, ~1% of oxytocin 95 is excreted in urine (15).
96
After entering the blood, oxytocin rapidly penetrates extravascular fluid, but does not 97 cross the blood-brain barrier in appreciable amounts. In an early study, Ermisch et al. gave The effectiveness of the blood-brain barrier for oxytocin was measured by Mens et 104 al., who injected 5µg subcutaneously in rats, increasing plasma concentrations 500-fold to 105 ~38,600pg/ml (10). Increases in CSF were modest; concentrations increased from ~40pg/ml 106 to ~150pg/ml. The authors calculated that just 0.002% of the injected oxytocin had reached 107 the CNS after 10min, when CSF concentrations were maximal. 
121
The slow disappearance of oxytocin from blood after intranasal application suggests that 122 large amounts reach an extravascular pool from which it slowly leaches into the circulation.
123
Ang and Jenkins studied the brain penetration of radiolabelled vasopressin given i.v., 124 and, importantly, measured how much label was still associated with intact peptide (19).
125
Vasopressin, like oxytocin, is a nonapeptide with a sulphur bridge, differing in just two 126 amino acids, and has similar bioavailability. Plasma vasopressin disappeared with the 127 expected bi-exponential decay, while CSF levels of the label were maximal after 50min; this 128 peak was <1% of that in plasma, and none of the label in CSF was associated with intact 129 peptide. They also gave labelled vasopressin intranasally, sampling CSF and plasma 40min 130 later. The concentration of label in CSF was ~5% of that in plasma, but whereas 16.5% of the 131 label in plasma was associated with intact peptide, none of the label recovered from CSF was.
132
Since then, six studies have measured CSF levels of oxytocin or vasopressin 133 following intranasal application. Born et al. reported that, after giving 40IU (80µg) in man,
134
CSF levels rose within 10min from ~5pg/ml to ~10pg/ml, increasing to ~20pg/ml at 60min sampled at 75min had CSF levels 64% higher than controls (at ~30pg/ml). In the same 144 month, the authors submitted a paper on fMRI changes in subjects tested 30min after 145 intranasal oxytocin (21). That paper does not cite the CSF data, or the fact that the fMRI 146 measurements were made at times when CSF oxytocin was unchanged. suggests that only ~5% of the oxytocin that is released in the rat brain reaches the CSF (1).
262
Thus, intranasally applied oxytocin might penetrate some brain regions yet not enter the CSF. However, many papers have used an ELISA on unextracted plasma, yielding values 284 of >300pg/ml (59-65). In response to caustic criticism (66), the manufacturers "strongly 285 recommended" that plasma samples should be extracted to avoid matrix interference (67), a 286 recommendation reinforced by Christensen et al. (68) , but this advice is still being ignored.
287
Any hope that the measured levels correlate with authentic oxytocin levels seems vain. Three 
290
One of those papers concludes that adolescent exposure to oxytocin increases plasma 291 oxytocin in adulthood, and it might be expected that this conclusion was drawn from data on 292 extracted plasma (70). Not so: the data from extracted samples showed no differences 293 between groups: instead, the authors built their interpretation on the measurements of 294 unextracted plasma.
295
The discrepancy between measurements in unextracted and extracted plasma is two and vasopressin in orphans was affected by early neglect, they reported levels that were, for 298 both peptides, nearly a million fold too high, after applying a method that was neither 299 sensitive enough or selective enough to measure either peptide in urine (72), a report that Oxytocin is released into the brain in large amounts from the soma and dendrites of 313 neurons that project to the pituitary-but this is semi-independent of axonal release, being were only elevated for 15min postpartum whereas those in CSF were increased for >120min. showed, by simulations and experiments, how easy it is to accumulate "statistically 369 significant" evidence for a false hypothesis.
370
Pre-registering trials, declaring primary outcomes in advance, specifying statistical 371 methods to be applied, and making data openly available should minimise these problems.
372
Several recent trials conform to some of these conditions, particularly in reporting clear 373 primary outcomes. They show no effect of intranasal oxytocin on patients with schizophrenia 
